{"nctId":"NCT00300274","briefTitle":"Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection","startDateStruct":{"date":"2006-01"},"conditions":["Graft Rejection"],"count":721,"armGroups":[{"label":"everolimus 1.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: everolimus","Drug: cyclosporine","Drug: corticosteroids"]},{"label":"everolimus 3.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: everolimus","Drug: cyclosporine","Drug: corticosteroids"]},{"label":"mycophenolate mofetil","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: mycophenolate mofetil","Drug: cyclosporine","Drug: corticosteroids"]}],"interventions":[{"name":"everolimus","otherNames":["Zortress®","Certican®"]},{"name":"mycophenolate mofetil","otherNames":["Cellcept®"]},{"name":"cyclosporine","otherNames":["Neoral®"]},{"name":"corticosteroids","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female cardiac recipients 18-70 years of age undergoing primary heart transplantation.\n* The graft must be functional at time of randomization.\n\nExclusion Criteria:\n\n* Patients who are recipients of multiple solid organ transplants or tissue transplants or have previously received organ transplants.\n* Patients who are recipients of ABO incompatible transplants.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Composite Efficacy Failure at 12 Months","description":"Composite efficacy failure was defined as Biopsy Proven Acute Rejection(BPAR) of International Society for Heart and Lung Transplantation(ISHLT) grade ≥3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.\n\nIdentification of acute rejection was based on the local pathologist's evaluation of endomyocardial biopsy slides.\n\nHemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤30% or 25% lower than Baseline or Fractional shortening ≤20% or 25% lower than Baseline and/or use of inotropic treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"35.1","spread":null},{"groupId":"OG002","value":"33.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months","description":"Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 316 (start day of the Month 12 visit window).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"11.9","spread":null},{"groupId":"OG002","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months","description":"GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:\n\nGFR \\[mL/min/1.73m\\^2\\] = 186.3\\*(C\\^-1.154)\\*(A\\^-0.203)\\*G\\*R where C is the serum concentration of creatinine \\[mg/dL\\] A is age \\[years\\] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.21","spread":"23.113"},{"groupId":"OG001","value":"59.78","spread":"23.141"},{"groupId":"OG002","value":"64.37","spread":"28.365"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Average Maximum Intimal Thickness at Month 12","description":"Maximum intimal thickness was assessed using Intravascular Ultrasound (IVUS). IVUS is a technique for taking ultrasound pictures of the wall of an artery from inside the artery itself. It shows the thickness of the artery wall and any narrowing of the artery.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.052"},{"groupId":"OG001","value":"0.04","spread":"0.06"},{"groupId":"OG002","value":"0.07","spread":"0.110"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12","description":"Cardiac allograft vasculopathy is defined as a 0.5 mm increase in maximum intimal thickness as measured by Intravascular Ultrasound (IVUS) in at least one matched slice between baseline and Month 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"21.6","spread":null},{"groupId":"OG002","value":"26.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12","description":"Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.\n\nHemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/or use of inotropic treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"25.6","spread":null},{"groupId":"OG002","value":"24.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG002","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Composite Efficacy Failure at 24 Months","description":"Composite efficacy failure was defined as Biopsy Proven Acute Rejection (BPAR) of International Society for Heart and Lung Transplantation grade ≥ 3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.\n\nIdentification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.\n\nHemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline and/or use of inotropic treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null},{"groupId":"OG001","value":"41.1","spread":null},{"groupId":"OG002","value":"41.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months","description":"Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 631 (start day of 24 Month visit window).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null},{"groupId":"OG001","value":"16.1","spread":null},{"groupId":"OG002","value":"15.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months","description":"GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:\n\nGFR \\[mL/min/1.73m\\^2\\] = 186.3\\*(C\\^-1.154)\\*(A\\^-0.203)\\*G\\*R\n\nC is the serum concentration of creatinine \\[mg/dL\\] A is age \\[years\\] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.50","spread":"22.438"},{"groupId":"OG001","value":"61.84","spread":"25.247"},{"groupId":"OG002","value":"64.52","spread":"23.764"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24","description":"Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.\n\nHemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/ or use of inotropic treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"27.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"11.9","spread":null},{"groupId":"OG002","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":209,"n":279},"commonTop":["Hypertension","Oedema peripheral","Anaemia","Pericardial effusion","Headache"]}}}